Straight Path Wealth Management - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Straight Path Wealth Management ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$19,116
-16.3%
16,2000.0%0.01%
-18.8%
Q2 2023$22,842
-6.0%
16,2000.0%0.02%
-15.8%
Q1 2023$24,300
+28.2%
16,2000.0%0.02%
+5.6%
Q4 2022$18,954
+5.3%
16,2000.0%0.02%
+12.5%
Q3 2022$18,000
-30.8%
16,2000.0%0.02%
-36.0%
Q2 2022$26,000
+4.0%
16,2000.0%0.02%
+19.0%
Q1 2022$25,000
-37.5%
16,2000.0%0.02%
-40.0%
Q4 2021$40,00016,2000.04%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders